Showing 4541-4550 of 5805 results for "".
- Expert Second Opinion Improves Reliability of Melanoma Diagnoseshttps://practicaldermatology.com/news/expert-second-opinion-improves-reliability-of-melanoma-diagnoses/2460179/Obtaining a second opinion from pathologists who are board certified or have fellowship training in dermatopathology may improve the accuracy and reliability of diagnosing melanoma, according to a new study in JAMA Network Open. To evaluate the impact of obtaining second o
- Above-the-Neck Melanoma More Likely to Spreadhttps://practicaldermatology.com/news/above-the-neck-melanoma-more-likely-to-spread/2460176/Malignant melanoma above the neck is more likely to spread, according to new findings presented at the 28th European Dermato-Venereology Society Congress in Madrid. New results from a descriptive, 6-month clinical study suggest that malignant melanoma that develops on the ne
- EADV News: Psoriasis Largely Undertreated, Travels with Anxietyhttps://practicaldermatology.com/news/eadv-news-psoriasis-largely-undertreated-travels-with-anxiety/2460175/Many psoriasis patients remain un- or undertreated, with an average diagnosis time of five years, according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. In the study of 650 psoriasis patients in Germany, more than half of patients (56 percen
- Pediatric AD Takes Its Toll on Caregiver Emotional Wellbeinghttps://practicaldermatology.com/news/ad-takes-its-toll-on-caregiver-emotional-wellbeing/2460173/Family members and caregivers of children with atopic dermatitis (AD) may be at increased risk for anxiety and depression, according to new research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Researchers from the PHIUniversity Clinic of Dermatol
- Galderma Advances Phase 3 Clinical Study with Nemolizumab in Moderate to Severe Atopic Dermatitishttps://practicaldermatology.com/news/galderma-advances-phase-3-clinical-study-with-nemolizumab-in-moderate-to-severe-atopic-dermatitis/2460171/Galderma has enrolled the first patients in a new Phase 3 clinical study with nemolizumab, an investigational therapy in adult patients with moderate to severe atopic dermatitis. This randomized, double-blinded, placebo-controlled study will assess the efficacy and safety of nemolizumab in subjec
- Study: Tape Strips Can Assess Biomarkers in Pediatric ADhttps://practicaldermatology.com/news/study-tape-strips-can-assess-biomarkers-in-pediatric-ad-1/2460167/Tape strips may serve as a minimally invasive approach to assess biomarkers for early-onset pediatric atopic dermatitis (AD), finds a study in JAMA Dermatology. In the study of 51 children younger than 5 years, 21 children had moderate to severe AD with less than 6 months of di
- Burt's Bees: Data Support Efficacy of Natural Skincarehttps://practicaldermatology.com/news/burts-bees-data-support-efficacy-of-natural-skincare/2460166/Products and ingredients in the Burt’s Bees natural skincare line provide documented benefits, according to studies presented at the second annual Integrative Dermatology Symposium (IDS) in San Diego this month. Among the findings is evidenc
- Industry News: Galderma Will Go It Alonehttps://practicaldermatology.com/news/industry-news-galderma-will-go-it-alone/2460161/It’s official. Galderma is going it alone after completion of CHF 10.2 billion acquisition of Nestlé Skin Health, first announced in May 2019. The acquisition, led by a consortium comprising the EQT VIII fund (“EQT”), Luxinva (a wholly-owned subsidiary of
- National Eczema Association's New Campaign Exposes The “Real Eczema”https://practicaldermatology.com/news/national-eczema-associations-new-campaign-exposes-the-real-eczema/2460160/October's Eczema Awareness Month efforts will focus on unhiding the realities of eczema with the National Eczema Association's (NEA) #TheRealEczema campaign. The new campaign includes a video, "The Real Eczema," featur
- Neutrogena’s Newest Collection Addresses Dull, Uneven Skinhttps://practicaldermatology.com/news/neutrogenas-newest-collection-addresses-dull-uneven-skin/2460157/Nearly two-thirds (66 percent) of U.S. millennial women age 23-38 have noticed a shift in their skin's brightness, according to a poll of more 1,100 U.S. women aged 18 and older sponsored by Neutrogena. Neutrogena’s new four-part collection,